Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo

doi:10.18632/oncotarget.7130

PMC full text:

Oncotarget. 2016 Mar 1; 7(9): 9876–9889.

Published online 2016 Feb 2. doi: 10.18632/oncotarget.7130

Copyright/LicenseRequest permission to reuse: Copyright : © 2016 Onken et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

<< PrevFigure 1Next >>

Figure 1

An external file that holds a picture, illustration, etc.
Object name is oncotarget-07-09876-g001.jpg

(A) RTK-AXL expression of U118MG and SF126 cells in vitro. (B) RTK-AXL expression of U118MG and SF126 xenografts in vivo. Scale bar indicates 50 μm. (C) left image: Western blot showing base line expression of RTK-AXL in cell lysates of U118MG and SF126 (− = negative control). (C) right image: Western blot analysis of changes in the phosphorylation of RTK-AXL under starving conditions compared to standard culture conditions (− = negative control). (D) IC₅₀ of U118MG and SF126 cells after treatment with BMS-777607 for 4 and 12 hours.

Figure 1

Images in this article

Click on the image to see a larger version.